A comparison of three commercial platforms for urinary NGAL in critically ill adults

Abstract

All three methods for uNGAL showed acceptable performance for the tested parameters and are comparable with each other at clinically relevant cutoffs. However, Architect yields lower results than the other two methods, with a bias more pronounced at higher uNGAL concentrations, suggesting additional standardization efforts will likely be necessary to better harmonize the uNGAL methods at various clinically relevant cutoffs.

Neutrophil Gelatinase-Associated Lipocalin Measured on Clinical Laboratory Platforms for the Prediction of Acute Kidney Injury and the Associated Need for Dialysis Therapy: A Systematic Review and Meta-analysis

“…102 However, interassay variability should be taken into account when interpreting results from the various platforms measuring NGAL, which may affect the transferability of results. 102,103 Our analyses were limited to an adult population and did not include unpublished studies potentially influencing the results of systematic reviews. 104 Not all authors who were initially requested to contribute to the individualstudy-data meta-analysis responded or provided reanalyzed data.…”

Kidney injury biomarkers in an academic hospital setting: where are we now?

“…For example, state-of-the art analytical performance of NGAL immunoassays for chemical analysers is CV A = 1.2-5.2%. [153][154][155] A novel technique that has recently been introduced in the clinical laboratory for protein quantitation is mass spectrometry (MS). MS is a highly specific technique with multiplexing capability and analysis of individual proteoforms, that has advantages over immunoassays.…”

Urinary Neutrophil Gelatinase-Associated Lipocalin as a Predictor of Acute Kidney Injury, Severe Kidney Injury, and the Need for Renal Replacement Therapy in the Intensive Care Unit

“…It was initially proposed by Mishra et al [ 14 ] in 2003, as an indicator for early renal injury secondary to renal hypoperfusion. Since then, it has been studied in a variety of clinical contexts [ 7 ], both in children and adults, including renal injury due to cancer [ 15 , 16 ], cancer chemotherapy [ 17 , 18 , 19 ], kidney surgery [ 20 ], kidney transplantation [ 21 , 22 ], cardiac surgery [ 23 , 24 , 25 , 26 , 27 ], and systemic illness, especially sepsis [ 8 , 28 , 29 , 30 ]. However, to date, uncertainty remains regarding the actual role of NGAL in the clinical setting, namely whether plasma or urinary NGAL (uNGAL) or a combination of the two is preferable, the best timing for NGAL acquisition, and the differences between the various commercially available NGAL assays [ 6 , 24 , 28 , 30 , 31 , 32 , 33 ].…”